Literature DB >> 14627700

Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.

Katharine L Sugars1, Rosemary Brown, Lynnette J Cook, Jina Swartz, David C Rubinsztein.   

Abstract

Huntington's disease (HD) is one of nine neurodegenerative diseases caused by an expanded polyglutamine (polyQ) tract within the disease protein. To characterize pathways induced early in HD, we have developed stable inducible PC12 cell lines expressing wild-type or mutant forms of huntingtin exon 1 fragments or the full-length huntingtin protein. Three cAMP response element-binding protein (CREB)-binding protein-dependent transcriptional pathways, regulated by cAMP response element (CRE), retinoic acid response element, and nuclear factor kappaB, show abnormalities in our exon 1 cell model. Of these, the CRE pathway shows the earliest disruption and is significantly down-regulated as early as 12 h following mutant htt transgene induction. This pathway is also the only one of the three that is similarly perturbed in our full-length HD model, where it is also down-regulated at an early time point, compatible with observations in HD brains. Reduced CRE-dependent transcription may contribute to polyQ disease pathogenesis because overexpression of transcriptionally active CREB, but not an inactive form of the protein, is able to protect against polyQ-induced cell death and reduce aggregation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627700     DOI: 10.1074/jbc.M310226200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

2.  Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.

Authors:  Ashu Johri; Anatoly A Starkov; Abhishek Chandra; Thomas Hennessey; Abhijeet Sharma; Sara Orobello; Ferdinando Squitieri; Lichuan Yang; M Flint Beal
Journal:  Neurodegener Dis       Date:  2011-07-15       Impact factor: 2.977

3.  CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.

Authors:  Yun-Sik Choi; Boyoung Lee; Hee-Yeon Cho; Iza B Reyes; Xin-An Pu; Takaomi C Saido; Kari R Hoyt; Karl Obrietan
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

4.  High resolution time-course mapping of early transcriptomic, molecular and cellular phenotypes in Huntington's disease CAG knock-in mice across multiple genetic backgrounds.

Authors:  Seth A Ament; Jocelynn R Pearl; Andrea Grindeland; Jason St Claire; John C Earls; Marina Kovalenko; Tammy Gillis; Jayalakshmi Mysore; James F Gusella; Jong-Min Lee; Seung Kwak; David Howland; Min Young Lee; David Baxter; Kelsey Scherler; Kai Wang; Donald Geman; Jeffrey B Carroll; Marcy E MacDonald; George Carlson; Vanessa C Wheeler; Nathan D Price; Leroy E Hood
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

5.  Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.

Authors:  Jun Wu; Hsin-Pei Shih; Vladimir Vigont; Lori Hrdlicka; Len Diggins; Carol Singh; Matt Mahoney; Richard Chesworth; Gideon Shapiro; Olga Zimina; Xuesong Chen; Qingqing Wu; Lyubov Glushankova; Michael Ahlijanian; Gerhard Koenig; Galina N Mozhayeva; Elena Kaznacheyeva; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-06-24

6.  cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila.

Authors:  Kanae Iijima-Ando; Priscilla Wu; Eric A Drier; Koichi Iijima; Jerry C P Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-11       Impact factor: 11.205

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

10.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.